About
EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This innovative therapy intends to improve cancer patients’ quality of life and compliance with cancer therapy.
Current treatment strategies and new developments focus on symptom reduction post-EGFR inhibition when our solution blocks the initial trigger causing skin toxicity, the drug-receptor interaction. The company new approach will prevent skin toxicity, enabling more cancer patients to go about their daily lives without compromising their anticancer treatment.
Its solution (SDT 011) is targeting a huge market with global unmet need. The market is also expected to substantially grow due to new combinations of cancer treatments with EGFRi and a potential product approval of new EGFRi bi-specific antibodies.
SDT 011 (EMR-001) is the first-to-market product in the pipeline of the company. Additional new candidate compounds are currently in development for Tyrosine Kinase Inhibitors’ induced skin toxicities that can substantially contribute to the market size.
Funding history · 1 round · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Emris Pharma founded?
- Emris Pharma was founded in May 2023.
- What is Emris Pharma's primary focus?
- Emris Pharma is developing a novel small molecule, topically administered, for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi) in cancer patients.
- What is the name of Emris Pharma's first-to-market product?
- Emris Pharma's first-to-market product in its pipeline is SDT 011, also known as EMR-001.
- Which organizations spun off Emris Pharma?
- Emris Pharma is a spin-off of Hadasit and Yissum, as announced in June 2023.
- What was Emris Pharma's initial funding round?
- Emris Pharma secured a Pre-Seed funding round in May 2023, with lead investors including NGT HealthCare II and the Israel Innovation Authority.
- How many employees does Emris Pharma currently have?
- Emris Pharma currently has 6 employees.
- Where is Emris Pharma headquartered?
- Emris Pharma is headquartered in Nazareth, Israel.
- What is the current product stage of Emris Pharma's developments?
- Emris Pharma's products are currently in the R&D stage.